Equities Analysts Offer Predictions for ARWR FY2024 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at Leerink Partnrs upped their FY2024 EPS estimates for shares of Arrowhead Pharmaceuticals in a research note issued on Wednesday, November 6th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will post earnings of ($3.59) per share for the year, up from their previous forecast of ($3.60). The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($4.31) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals’ Q4 2024 earnings at ($0.01) EPS and FY2025 earnings at ($2.45) EPS.

Several other equities research analysts have also weighed in on ARWR. Cantor Fitzgerald reissued an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. Royal Bank of Canada reissued an “outperform” rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, October 11th. B. Riley reiterated a “buy” rating and set a $55.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 12th. Finally, StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research note on Thursday, October 17th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $45.33.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $21.89 on Friday. The business has a 50-day moving average of $20.33 and a two-hundred day moving average of $23.48. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of -4.69 and a beta of 0.93. Arrowhead Pharmaceuticals has a 1 year low of $17.05 and a 1 year high of $39.83.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.80). During the same period in the previous year, the business posted ($0.96) EPS. The company’s revenue was down 100.0% on a year-over-year basis.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Fifth Third Bancorp raised its stake in Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 354 shares during the last quarter. Headlands Technologies LLC increased its holdings in shares of Arrowhead Pharmaceuticals by 7,696.8% in the first quarter. Headlands Technologies LLC now owns 2,417 shares of the biotechnology company’s stock valued at $69,000 after purchasing an additional 2,386 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Arrowhead Pharmaceuticals during the third quarter worth approximately $52,000. Meeder Asset Management Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 4,629.2% during the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 3,333 shares during the period. Finally, nVerses Capital LLC purchased a new position in Arrowhead Pharmaceuticals in the 2nd quarter valued at $96,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.